Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine with Gemcitabine and Oxaliplatin in Relapsed/Refractory Peripheral T Cell Lymphoma
KCT0004590Phase 2Recruiting
- Sponsor
- Boryung
- Start
- Nov 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine, gemcitabine, oxaliplatin in peripheral T-cell lymphoma (PTCL), sponsored by Boryung. Started Nov 2020; status: recruiting.
02
Drugs
decitabinegemcitabineoxaliplatin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on KCT0004590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004590.